Relationship between secretory leukocyte protease inhibitor and acute coronary syndrome

Abstract

Abstract:

ObjectiveTo explore the relationship between secretory leukocyte protease inhibitor (SLPI) and acute coronary syndrome (ACS).MethodsA total of 243 patients with ACS and 242 age- and gender- matched individuals with normal coronary arteries undergoing coronary angiography from July 2018 to September 2020 in Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine were enrolled. The serum SLPI level was detected by enzyme-linked immunosorbent assay, and the correlation between serum SLPI level and ACS was evaluated. Immunofluorescence was used to detect the localization of SLPI in ventricular aneurysm.ResultsThe serum SLPI level in ACS patients was significantly higher than that in healthy controls [(452.0±167.6) ng/Lvs. (420.5±154.3) ng/L,P=0.032]. Multivariate Logistic regression analysis showed that the increased serum SLPI level was an independent risk factor for ACS [odds ratio(OR)=1.309, 95% confidence interval (CI):(1.040-1.648),P=0.022]. Immunofluorescence showed SLPI was co-expressed with alpha-smooth muscle actin (α-SMA) in the ventricular aneurysm.ConclusionsSerum SLPI level is an independent risk factor for ACS, and SLPI is expressed in smooth muscle cell of ventricular aneurysm.

Key words:Acute coronary syndrome,Secretory leukocyte protease inhibitor,Ventricular aneurysm

CLC Number:

R543.3

JIN Yao, HUANG Hui, WU Zhijun. Relationship between secretory leukocyte protease inhibitor and acute coronary syndrome[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(04): 251-254.

Figures/Tables3

项目	对照组（n=242）	观察组（n=243）	t/χ²	P
男性[n(%)]	153(63.2)	169(69.6)	2.173	0.140
年龄(岁)	60.5±9.8	61.8±12.7	1.285	0.199
BMI (kg/m²)	24.77±3.37	24.98±5.13	0.541	0.589
收缩压(mmHg)	133.5±18.3	132.1±19.8	-0.818	0.414
舒张压(mmHg)	75.7±12.3	76.4±13.1	0.659	0.510
空腹血糖(mmol/L)	5.67±1.16	7.07±2.90	6.861	<0.001
HDL-C (mmol/L)	1.19±0.32	1.06±0.26	-4.925	<0.001
LDL-C (mmol/L)	3.30±11.59	3.06±1.04	-0.331	0.741
三酰甘油(mmol/L)	1.59±1.04	1.82±1.26	2.124	0.034
eGFR[mL/(min·1.73m²)]	87.8±13.7	86.3±15.5	-1.143	0.254
hsCRP (mg/L)	3.18±12.02	15.39±31.32	5.383	<0.001
SLPI (ng/L)	420.5±154.3	452.0±167.6	2.155	0.032

项目	β	SE	Waldχ²	OR（95% CI）	P
性别	0.411	0.299	1.881	1.508（0.838~2.712）	0.170
年龄（四分位）	0.186	0.166	1.266	1.205（0.871~1.666）	0.260
BMI（四分位）	-0.210	0.130	2.601	0.811（0.628~1.046）	0.107
收缩压（四分位）	-0.034	0.144	0.056	0.967（0.729~1.282）	0.814
舒张压（四分位）	-0.078	0.144	0.291	0.925（0.698~1.227）	0.590
空腹血糖（四分位）	0.351	0.128	7.489	1.421（1.105~1.827）	0.006
HDL-C（四分位）	-0.311	0.148	4.452	0.732（0.548~0.978）	0.035
LDL-C（四分位）	0.521	0.120	18.71	1.684（1.330~2.132）	<0.001
三酰甘油（四分位）	-0.150	0.142	1.116	0.861（0.652~1.137）	0.291
eGFR（四分位）	-0.058	0.145	0.161	0.943（0.709~1.254）	0.689
hsCRP（四分位）	1.121	0.135	68.77	3.067（2.353~3.997）	<0.001
SLPI（四分位）	0.269	0.117	5.250	1.309（1.040~1.648）	0.022

References14

[1]	Wang L, Jin Y. Noncoding RNAs as biomarkers for acute coronary syndrome[J]. Biomed Res Int, 2020, 2020: 3298 696.
[2]	Palaniyappan A, Uwiera RR, Idikio H, et al. Attenuation of increased secretory leukocyte protease inhibitor, matricellular proteins and angiotensin Ⅱ and left ventricular remodeling by candesartan and omapatrilat during healing after reperfused myocardial infarction[J]. Mol Cell Biochem, 2013, 376(1-2): 175-188. doi:10.1007/s11010-013-1565-2pmid:23361363
[3]	Song L, You W, Wang P, et al. Transcriptomic analysis of the association between diabetes mellitus and myocardial infarction[J]. Exp Clin Endocrinol Diabetes, 2019, 127(9): 603-614. doi:10.1055/a-0619-4412 URL
[4]	李少金, 肖水秀, 司徒永立, 等. 分泌型白细胞蛋白酶抑制剂与疾病关系的研究进展[J]. 青岛大学学报(医学版), 2018, 54(5): 620-624.
[5]	Majewski P, Majchrzak-Gorecka M, Grygier B, et al. Inhibitors of serine proteases in regulating the production and function of neutrophil extracellular traps[J]. Front Immunol, 2016, 7: 261. doi:10.3389/fimmu.2016.00261pmid:27446090
[6]	Tang R, Botchway BOA, Meng Y, et al. The inhibition of inflammatory signaling pathway by secretory leukocyte protease inhibitor can improve spinal cord injury[J]. Cell Mol Neurobiol, 2020, 40(7): 1067-1073. doi:10.1007/s10571-020-00799-1 URL
[7]	潘其重. 分泌性白细胞蛋白酶抑制剂研究进展[J]. 河北医药, 2011, 33(20): 3147-3149.
[8]	Zhong QQ, Wang X, Li YF, et al. Secretory leukocyte protease inhibitor promising protective roles in obesity-associated atherosclerosis[J]. Exp Biol Med (Maywood), 2017, 242(3): 250-257. doi:10.1177/1535370216672747 URL
[9]	Majchrzak-Gorecka M, Majewski P, Grygier B, et al. Secretory leukocyte protease inhibitor (SLPI), a multifunctional protein in the host defense response[J]. Cytokine Growth Factor Rev, 2016, 28: 79-93. doi:10.1016/j.cytogfr.2015.12.001 URL
[10]	Balderrama-Gutierrez G, Milovic A, Cook VJ, et al. An infection-tolerant mammalian reservoir for several zoonotic agents broadly counters the inflammatory effects of endotoxin[J]. mBio, 2021, 12(2): e00588-21.
[11]	Vafadarnejad E, Rizzo G, Krampert L, et al. Dynamics of cardiac neutrophil diversity in murine myocardial infarction[J]. Circ Res, 2020, 127(9): e232-e249.
[12]	Kongpol K, Nernpermpisooth N, Prompunt E, et al. Endothelial-cell-derived human secretory leukocyte protease inhibitor(SLPI) protects cardiomyocytes against ischemia/reperfusion injury[J]. Biomolecules, 2019, 9(11): 678. doi:10.3390/biom9110678 URL
[13]	Nernpermpisooth N, Prompunt E, Kumphune S. Anin vitroendothelial cell protective effect of secretory leukocyte protease inhibitor against simulated ischaemia/reperfusion injury[J]. Exp Ther Med, 2017, 14(6): 5793-5800. doi:10.3892/etm.2017.5272pmid:29285123
[14]	Mongkolpathumrat P, Kijtawornrat A, Prompunt E, et al. Post-ischemic treatment of recombinant human secretory leukocyte protease inhibitor (rhSLPI) reduced myocardial ischemia/reperfusion injury[J]. Biomedicines, 2021, 9(4): 422. doi:10.3390/biomedicines9040422 URL